Literature DB >> 9168232

Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques.

S V Joag1, Z Li, L Foresman, D M Pinson, R Raghavan, W Zhuge, I Adany, C Wang, F Jia, D Sheffer, J Ranchalis, A Watson, O Narayan.   

Abstract

By animal-to-animal passage in macaques we derived a pathogenic chimeric simian-human immunodeficiency virus (SHIV) that caused CD4+ T cell loss and AIDS in pigtail macaques and used it to inoculate 20 rhesus and pigtail macaques by the intravaginal and intravenous routes. On the basis of the outcome of infection and patterns of CD4+ T cell loss and viral load, disease was classified into four patterns: acute, subacute, chronic, and nonprogressive infection. During the study period, 15 of the 20 animals developed fatal disease, including AIDS, encephalitis, pneumonia, and severe anemia. Opportunistic pathogens identified in these animals included Pneumocystis, cytomegalovirus, Cryptosporidium, Toxoplasma, and Candida. No single parameter by itself predicted outcome, although a combination of low CD4+ T cell counts in blood, high plasma virus levels, and presence of autoantibodies to red blood cells reliably predicted a fatal outcome. Five animals (25%) died within 3 months of inoculation and constituted the group with acute disease, whereas the nine animals (45%) with subacute disease died between 3 and 8 months postinoculation. This 70% mortality within 8 months is significantly shorter than in HIV-1-infected human beings, of whom 70% develop fatal disease a decade after infection. SHIV infection in macaques provides a useful model with which to evaluate antiviral strategies, combining all the advantages of the SIVmac system, yet using a virus bearing the envelope gene of HIV-1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168232     DOI: 10.1089/aid.1997.13.635

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  23 in total

1.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Persistent pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS.

Authors:  Timothy W Shipley; Heather M Kling; Alison Morris; Sangita Patil; Jan Kristoff; Siobhan E Guyach; Jessica E Murphy; Xiuping Shao; Frank C Sciurba; Robert M Rogers; Thomas Richards; Paul Thompson; Ronald C Montelaro; Harvey O Coxson; James C Hogg; Karen A Norris
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

3.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.

Authors:  Ronald S Veazey; Thomas J Ketas; Jason Dufour; Terri Moroney-Rasmussen; Linda C Green; P J Klasse; John P Moore
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

5.  Simian-human immunodeficiency virus (SHIV) containing the nef/long terminal repeat region of the highly virulent SIVsmmPBj14 causes PBj-like activation of cultured resting peripheral blood mononuclear cells, but the chimera showed No increase in virulence.

Authors:  E B Stephens; S Mukherjee; Z Q Liu; D Sheffer; R Lamb-Wharton; K Leung; W Zhuge; S V Joag; Z Li; L Foresman; I Adany; O Narayan
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.

Authors:  Ranajit Pal; David Venzon; Sampa Santra; Vaniambadi S Kalyanaraman; David C Montefiori; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Janos Nacsa; Yvette Edghill-Smith; Marcin Moniuszko; Zdenek Hel; Igor M Belyakov; Jay A Berzofsky; Robyn Washington Parks; Phillip D Markham; Norman L Letvin; Jim Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques.

Authors:  Thomas M Yankee; Darlene Sheffer; Zhengian Liu; Sukhbir Dhillon; Fenglan Jia; Yahia Chebloune; Edward B Stephens; Opendra Narayan
Journal:  Virology       Date:  2008-11-05       Impact factor: 3.616

Review 9.  Nonhuman primate models of NeuroAIDS.

Authors:  Rachel Williams; Sirosh Bokhari; Peter Silverstein; David Pinson; Anil Kumar; Shilpa Buch
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

10.  Comparison of the effects of pathogenic simian human immunodeficiency virus strains SHIV-89.6P and SHIV-KU2 in cynomolgus macaques.

Authors:  Santosh N Pawar; Joshua T Mattila; Timothy J Sturgeon; Philana Ling Lin; Opendra Narayan; Ronald C Montelaro; Joanne L Flynn
Journal:  AIDS Res Hum Retroviruses       Date:  2008-04       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.